Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials

  1. Gettinger, S.N.
  2. Huber, R.M.
  3. Kim, D.-W.
  4. Bazhenova, L.
  5. Hansen, K.H.
  6. Tiseo, M.
  7. Langer, C.J.
  8. Paz-Ares Rodríguez, L.G.
  9. West, H.L.
  10. Reckamp, K.L.
  11. Weiss, G.J.
  12. Smit, E.F.
  13. Hochmair, M.J.
  14. Kim, S.-W.
  15. Ahn, M.-J.
  16. Kim, E.S.
  17. Groen, H.J.M.
  18. Pye, J.
  19. Liu, Y.
  20. Zhang, P.
  21. Vranceanu, F.
  22. Camidge, D.R.
Revista:
JTO Clinical and Research Reports

ISSN: 2666-3643

Any de publicació: 2022

Volum: 3

Número: 9

Tipus: Article

DOI: 10.1016/J.JTOCRR.2022.100385 GOOGLE SCHOLAR lock_openAccés obert editor

Objectius de Desenvolupament Sostenible

Font de les dades: Scopus